DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: The DIABEO ® system (DS) is a telemedicine solution that combines a mobile app for patients with a web portal for health care providers. DS allows real-time monitoring of basal-bolus insulin therapy as well as therapeutic decision-making, integrating both basal and bolus dose calculation. Real-life studies have shown a very low rate of use of mobile health applications by patients. Therefore, we conducted a large randomized controlled trial study to investigate the efficacy of DS in conditions close to real life (TELESAGE study). Methods: TELESAGE was a multicenter, randomized, open study with three parallel arms: arm 1 (standard care), arm 2 (DIABEO alone), and arm 3 (DIABEO+telemonitoring by trained nurses). The primary outcome assessed the reduction in HbA 1c levels after a 12-month follow-up. Results: Six hundred sixty-five patients were included in the study. Participants who used DIABEO once or more times a day (DIABEO users) showed a significant and meaningful reduction of HbA 1c versus standard care after a 12-month follow-up: mean difference −0.41% for arm 2—arm 1 ( P = 0.001) and −0.51% for arm 3—arm 1 ( P ≤ 0.001). DIABEO users included 25.1% of participants in arm 2 and 37.6% in arm 3. In the intention-to-treat population, HbA 1c changes and incidence of hypoglycemia were comparable between arms. Conclusions: A clinical and statistically significant reduction in HbA 1c levels was found in those patients who used DIABEO at least once a day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barriers to diabetes management: patient and provider factors
Nam, S., Chesla, C., Stotts, N. A., Kroon, L., & Janson, S. L. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.002 · Cited by 680 · cited 1×
“However, self-managed glycemic control is often suboptimal, particularly for diabetic patients under intensive basal-bolus insulin regimens.(3,4) Among others, many diabetic patients struggle in daily life to calculate and inject appropriate doses of basal and/or meal insulin, leading to episodes of hypo or hyperglyce…”
BackgroundShan, R., Sarkar, S., & Martin, S. S. (2019) · Diabetologia · doi:10.1007/s00125-019-4864-7 · Cited by 339 · cited 1×
“published in peer-reviewed publications, as well as regulatory clearance from the EMA or the FDA (Food and Drug Administration).(8,19,20) The ‘‘Diabetes Interactive Diary’’ app software is a carbohydrate/bolus calculator, assisted by doctor/patient communication through a short message service.”
BackgroundBonoto, B. C., de Araújo, V. E., Godói, I. P., de Lemos, L. L. P., Godman, B., Bennie, M., Diniz, L. M., & Junior, A. A. G. (2017) · JMIR mhealth and uhealth · doi:10.2196/mhealth.6309 · Cited by 294 · cited 1×
“published in peer-reviewed publications, as well as regulatory clearance from the EMA or the FDA (Food and Drug Administration).(8,19,20) The ‘‘Diabetes Interactive Diary’’ app software is a carbohydrate/bolus calculator, assisted by doctor/patient communication through a short message service.”
BackgroundCharpentier, G., Benhamou, P.-Y., Dardari, D., Clergeot, A., Franc, S., Schaepelynck-Belicar, P., Catargi, B., Melki, V., Chaillous, L., Farret, A., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1259 · Cited by 292
Self-citationEffect of self-monitoring on long-term patient engagement with mobile health applications
Lee, K., Kwon, H., Lee, B., Lee, G., Lee, J. H., Park, Y. R., & Shin, S.-Y. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201166 · Cited by 132
Crowley, M. J., Holleman, R., Klamerus, M. L., Bosworth, H. B., Edelman, D., & Heisler, M. (2014) · Chronic Illness · doi:10.1177/1742395314523653 · Cited by 68 · cited 1×
“However, self-managed glycemic control is often suboptimal, particularly for diabetic patients under intensive basal-bolus insulin regimens.(3,4) Among others, many diabetic patients struggle in daily life to calculate and inject appropriate doses of basal and/or meal insulin, leading to episodes of hypo or hyperglyce…”
Background
Cited by
Moschonis, G., Siopis, G., Jung, J., Eweka, E., Willems, R., Kwasnicka, D., Asare, B. Y.-A., Kodithuwakku, V., Verhaeghe, N., Vedanthan, R., et al. (2023) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00233-3 · Cited by 149
Hangaard, S., Laursen, S. H., Andersen, J. D., Kronborg, T., Vestergaard, P., Hejlesen, O., & Udsen, F. W. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211064633 · Cited by 55
Tarricone, R., Petracca, F., Svae, L., Cucciniello, M., & Ciani, O. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105091 · Cited by 26
“%) adopted apps with some form of automatic support based on algorithms directed at adjusting the insulin dose, 69,76,93,95,97 – 101 providing customized messages based on input data, 60,63,64,77,86,88,102,103 modifying caloric intake and diet habits, 66,96,104 or tailoring physical activity…”
Method
Metadata
- Authors
- Franc, S., Hanaire, H., Benhamou, P.-Y., Schaepelynck, P., Catargi, B., Farret, A., Fontaine, P., Guerci, B., Reznik, Y., Jeandidier, N., Penfornis, A., Borot, S., Chaillous, L., Serusclat, P., Kherbachi, Y., d'Orsay, G., Detournay, B., Simon, P., & Charpentier, G.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2020-12-01
- Volume
- 22
- Issue
- 12
- Pages
- 904-911
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W3025999980
- Cited by
- 38
- References
- 6
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen. https://app.cochat.ai/papers/10.1089/dia.2020.0021
- The paper
- Franc, S., Hanaire, H., Benhamou, P.-Y., Schaepelynck, P., Catargi, B., Farret, A., Fontaine, P., Guerci, B., Reznik, Y., Jeandidier, N., Penfornis, A., Borot, S., Chaillous, L., Serusclat, P., Kherbachi, Y., d'Orsay, G., Detournay, B., Simon, P., & Charpentier, G. (2020). DIABEO System Combining a Mobile App Software With and Without Telemonitoring Versus Standard Care: A Randomized Controlled Trial in Diabetes Patients Poorly Controlled with a Basal-Bolus Insulin Regimen. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2020.0021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.